Search results for "Different"

showing 10 items of 8549 documents

Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma

1997

Peptides derived from melanocyte differentiation antigens have been identified as targets for MHC class I-restricted cytolytic T lymphocytes (CTLs) in human melanoma Regression of antigen-expressing tumors as well as selection of antigen-loss variants in the presence of antigen-specific CTLs have previously been reported. In the present study, we determined the expression of the melanocyte differentiation antigens Melan A/MART-1 and tyrosinase by mRNA analysis and by immunohistochemical staining with the monoclonal antibodies (MAbs) A103 and T311. Co-expression of Melan A/MART-1 and tyrosinase was detected by both methods in 18/20 melanomas tested. However, immunohistochemistry provided add…

AdultMaleCancer ResearchSkin Neoplasmsmedicine.drug_classBiopsyGenes MHC Class I10050 Institute of Pharmacology and Toxicology610 Medicine & healthMonoclonal antibodyPolymerase Chain ReactionMART-1 AntigenMelanocyte differentiationAntigenAntigens NeoplasmMHC class IHLA-A2 AntigenmedicineHumans1306 Cancer ResearchRNA MessengerMelanomaAgedDNA PrimersAged 80 and overbiologyMonophenol MonooxygenaseLiver NeoplasmsMiddle AgedImmunohistochemistryNeoplasm ProteinsCytolysisCTL*OncologyTumor progressionLymphatic MetastasisImmunologyCancer researchbiology.proteinImmunohistochemistry570 Life sciences; biologyFemale2730 Oncology
researchProduct

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

2005

BACKGROUND In this study, the authors analyzed the efficacy and safety of gemtuzumab ozogamicin (GO) (Mylotarg®), an antibody-targeted chemotherapy for CD33-positive acute myeloid leukemia (AML). METHODS Patients with CD33-positive AML in first recurrence were entered in 3 open-label, single-arm, Phase II studies. Patients received monotherapy with GO 9 mg/m2 as a 2-hour intravenous infusion in 2 doses separated by 2 weeks. Patients were evaluated for remission, survival, and treatment-emergent adverse events. RESULTS Two hundred seventy-seven patients (median age, 61 yrs) were treated with GO, and 71 patients (26%) achieved remission, which was defined as ≤ 5% blasts in the bone marrow wit…

AdultMaleCancer Researchmedicine.medical_specialtyMyeloidMaximum Tolerated DoseGemtuzumab ozogamicinmedicine.medical_treatmentCD33Sialic Acid Binding Ig-like Lectin 3Antigens Differentiation MyelomonocyticHematopoietic stem cell transplantationNeutropeniaAntibodies Monoclonal HumanizedGastroenterologyRisk AssessmentSeverity of Illness IndexDrug Administration ScheduleClinical Trials Phase II as TopicAntigens CDRecurrenceInternal medicinemedicineHumansSingle-Blind MethodSurvival rateAgedAged 80 and overChemotherapyDose-Response Relationship Drugbusiness.industryAntibodies MonoclonalMiddle Agedmedicine.diseaseGemtuzumabSurgerySurvival RateLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureAminoglycosidesTreatment OutcomeOncologyEvaluation Studies as TopicFemalebusinessmedicine.drugFollow-Up StudiesCancer
researchProduct

Diagnosing and staging of pancreatic carcinoma-what is necessary?

1998

The aim of the present prospective observational study was to diagnose and stage pancreatic carcinoma with a minimum of diagnostic procedures. Our experiences in 307 patients with a histologically confirmed pancreatic carcinoma show that for diagnosing pancreatic carcinoma sonography and computed tomography are sufficient in 95% of the cases. The combination of both has a sensitivity equal to that of endoscopic retrograde cholangiopancreatography (ERCP; 96.8 vs. 98.7%; n.s., χ<sup>2</sup> test). ERCP is only indicated in cases with negative sonography and computed tomography, and suspicion of pancreatic cancer. For tumor staging, the routine performance of angiography cannot be …

AdultMaleCancer Researchmedicine.medical_specialtyPancreatic diseaseCA-19-9 AntigenDiagnosis DifferentialCarcinoembryonic antigenPancreatic cancerBiomarkers TumorMedicineHumansProspective StudiesStage (cooking)AgedNeoplasm StagingUltrasonographyAged 80 and overCholangiopancreatography Endoscopic RetrogradeEndoscopic retrograde cholangiopancreatographymedicine.diagnostic_testbiologybusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseCarcinoembryonic AntigenPancreatic Neoplasmsmedicine.anatomical_structureOncologyAngiographybiology.proteinFemaleRadiologyDifferential diagnosisbusinessPancreasTomography X-Ray ComputedOncology
researchProduct

Basaloid squamous cell carcinoma of the esophagus: diagnosis and prognosis.

1997

BACKGROUND. Basaloid squamous cell carcinoma (BSCC) is a recently recognized, poorly differentiated variant of squamous cell carcinoma (SCC), which is located predominantly in the upper aerodigestive tract. METHODS. In this study, clinical and pathologic parameters of 17 BSCCs and 133 typical SCCs of the esophagus that underwent potentially curative resection (no distant metastases, no residual tumor) were compared. In addition, light microscopic, electron microscopic, and immunohistochemical features of BSCC were investigated, to determine whether this type of carcinoma could be differentiated from other poorly differentiated carcinomas of the esophagus. RESULTS. Light microscopic study sh…

AdultMaleCancer Researchmedicine.medical_specialtyPathologyEsophageal NeoplasmsApoptosisEpitheliumDiagnosis DifferentialCytokeratinNecrosisSex FactorsCarcinoma BasosquamousmedicineCarcinomaHumansNeoplasm InvasivenessEsophagusBasaloid Squamous Cell CarcinomaAgedNeoplasm StagingAged 80 and overMucous Membranebusiness.industryCarcinoma in situS100 ProteinsAge FactorsCell DifferentiationMiddle Agedmedicine.diseasePrognosisAntigens DifferentiationImmunohistochemistryActinsSurvival Ratestomatognathic diseasesMicroscopy Electronmedicine.anatomical_structureOncologyEpidermoid carcinomaDysplasiaCarcinoma Squamous CellKeratinsHistopathologyFemalebusinessCarcinoma in SituCell DivisionCancer
researchProduct

Posttraumatic stress, depression and anxiety among adult long-term survivors of cancer in adolescence.

2010

Abstract Background To determine the prevalence of posttraumatic stress, depression and anxiety in adults who have survived cancer (⩾5 years) diagnosed in adolescence, as compared to healthy controls. Patients and methods Survivors (n = 820) of cancer during adolescence (age M = 30.4 ± 6.0 years; M = 13.7 ± 6.0 years since diagnosis) and 1027 matched controls without history of cancer (age M = 31.5 ± 6.9 years) completed standardised questionnaires measuring posttraumatic stress, depression and anxiety. Additionally, sub-groups of 202 survivors and 140 controls with elevated scores received structured interviews to ascertain DSM-IV-diagnoses. Results A total of 22.4% of the survivors report…

AdultMaleCancer Researchmedicine.medical_specialtyPediatricsAdolescentStress Disorders Post-TraumaticYoung AdultNeoplasmsSurveys and QuestionnairesEpidemiologyPrevalenceMedicineHumansSurvivorsYoung adultPsychiatryDepression (differential diagnoses)Analysis of VarianceDepressive Disorderbusiness.industryCase-control studyOdds ratioMiddle Agedmedicine.diseaseAnxiety DisordersOncologyCase-Control StudiesAnxietyFemalemedicine.symptombusinessPsychosocialAnxiety disorderEuropean journal of cancer (Oxford, England : 1990)
researchProduct

CONSISTENT BONE MARROW-DERIVED CELL MOBILIZATION FOLLOWING REPEATED SHORT COURSES OF GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH AMYOTROPH…

2009

Background and aims. The aim of this study was to evaluate and characterize the feasibility and safety of bone marrow-derived cell (BMC) mobilization following repeated courses of granulocyte-colony stimulating factor (G-CSF) in patients with amyotrophic lateral sclerosis (ALS). Methods. Between January 2006 and March 2007, 26 ALS patients entered a multicenter trial that included four courses of BMC mobilization at 3-month intervals. In each course, G-CSF (5 mu g/kg b.i.d.) was administered for four consecutive days; 18% mannitol was also given. Mobilization was monitored by flow cytometry analysis of circulating CD34(+) cells and by in vitro colony assay for clonogenic progenitors. Co-exp…

AdultMaleCancer Researchmedicine.medical_specialtySLa - trial clinico - C-GSFImmunologyAntigens CD34Bone Marrow CellsDrug Administration ScheduleColony-Forming Units AssayCell MovementInternal medicineMulticenter trialmedicineImmunology and AllergyHumansCell LineageProspective StudiesAmyotrophic lateral sclerosisProspective cohort studyGenetics (clinical)Hematopoietic Stem Cell MobilizationNeuronsTransplantationMobilizationbusiness.industryStem CellsAmyotrophic Lateral SclerosisGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationCell BiologyMiddle Agedmedicine.diseaseHematopoietic Stem CellsBone Marrow-Derived CellHematopoietic Stem Cell MobilizationSurgeryGranulocyte colony-stimulating factorNerve RegenerationSettore MED/26 - NEUROLOGIAGranulocyte macrophage colony-stimulating factorTreatment OutcomeOncologyBiological MarkersFemalebusinessNeurogliaBiomarkersmedicine.drug
researchProduct

Expression of cysteine proteinases cathepsins B and K and of cysteine proteinase inhibitor cystatin C in giant cell tumor of tendon sheath.

2001

The expression of cysteine proteinases cathepsins B and K and of the endogenous inhibitor of cysteine proteinases, cystatin C, was investigated in tissue specimens of patients with giant cell tumor of tendon sheath (GCTTS). Expression of both enzymes was examined by immunohistochemistry in tissue specimens of 14 patients with GCTTS. Applying double-labeling techniques, the coexpression of cathepsin B and its major endogenous inhibitor cystatin C was additionally studied. Cells expressing the respective proteins were further characterized with the macrophage markers HAM56 and anti-CD68 (clone PG-M1). Cathepsin B could be detected in numerous HAM56-positive mononuclear cells (MC), but only in…

AdultMaleCathepsin KAntigens Differentiation MyelomonocyticCathepsin ECell CountCathepsin FBiologyCysteine Proteinase InhibitorsGiant CellsCathepsin BPathology and Forensic MedicineCathepsin CCathepsin BImmunoenzyme TechniquesTendonsCathepsin OCathepsin HAntigens CDCathepsin L1HumansCystatin CCathepsin SAgedMuscle NeoplasmsGiant Cell TumorsAntibodies MonoclonalMiddle AgedMolecular biologyCathepsinsCystatinsBiochemistryLeukocytes MononuclearFemaleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
researchProduct

Calf Blood Compound (CFC) and Homeopathic Drug Induce Differentiation of Primary Human Skeletal Muscle Cells.

2019

AbstractThe use of injections to treat structural muscle injuries is controversially discussed. In our controlled in vitro study, we investigated the biological impact of Actovegin and Traumeel alone and in combination on primary human skeletal muscle cells. Cells were characterized by immunofluorescence staining for myogenic factor 5 (Myf5) and MyoD, and cultured with or without Actovegin and / or Traumeel. The effects of these agents were assayed by cell viability and gene expression of the specific markers MyoD, Myf5, neural adhesion molecule (NCAM), and CD31. Myotube formation was determined by myosin staining. Neither Actovegin nor Traumeel showed toxic effects or influenced cell viabi…

AdultMaleCell SurvivalMuscle Fibers SkeletalDown-RegulationPhysical Therapy Sports Therapy and RehabilitationHeme030204 cardiovascular system & hematologyPharmacologyMyoD03 medical and health sciences0302 clinical medicineIn vivoGene expressionMyosinmedicineHumansOrthopedics and Sports MedicineViability assayCells CulturedAgedMyoD ProteinMineralsDose-Response Relationship DrugChemistryPlant ExtractsSkeletal muscleCell Differentiation030229 sport sciencesMiddle Agedmusculoskeletal systemCD56 AntigenPlatelet Endothelial Cell Adhesion Molecule-1medicine.anatomical_structureNeural cell adhesion moleculeMYF5Myogenic Regulatory Factor 5International journal of sports medicine
researchProduct

In Lysinuric Protein Intolerance system y+L activity is defective in monocytes and in GM-CSF-differentiated macrophages

2010

Abstract Background In the recessive aminoaciduria Lysinuric Protein Intolerance (LPI), mutations of SLC7A7/y+LAT1 impair system y+L transport activity for cationic amino acids. A severe complication of LPI is a form of Pulmonary Alveolar Proteinosis (PAP), in which alveolar spaces are filled with lipoproteinaceous material because of the impaired surfactant clearance by resident macrophages. The pathogenesis of LPI-associated PAP remains still obscure. The present study investigates for the first time the expression and function of y+LAT1 in monocytes and macrophages isolated from a patient affected by LPI-associated PAP. A comparison with mesenchymal cells from the same subject has been a…

AdultMaleCellular differentiationlcsh:MedicinePulmonary Alveolar ProteinosisBiologyMonocytesPathogenesisYoung AdultMacrophages AlveolarmedicineHumansGenetics(clinical)Pharmacology (medical)Amino Acid Metabolism Inborn ErrorsCells CulturedGenetics (clinical)Medicine(all)chemistry.chemical_classificationResearchFusion Regulatory Protein 1 Light ChainsLysinelcsh:RMesenchymal stem cellAmino Acid Transport System y+LGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationGeneral Medicinemedicine.diseaseLysinuric protein intoleranceMolecular biologyAmino acidGranulocyte macrophage colony-stimulating factorchemistryAminoaciduriaImmunologyPulmonary alveolar proteinosismedicine.drugOrphanet Journal of Rare Diseases
researchProduct

Modulatory effects of 1 Hz rTMS over the cerebellum on motor cortex excitability

2005

Clinical observations and data from animal experiments point to a physiological facilitatory influence of the deep cerebellar structures on the motor system through the cerebello-thalamo-cortical pathways. The aim of the present study was to explore the long-term effects of low-frequency (1 Hz) repetitive transcranial magnetic stimulation (rTMS) over the cerebellum on short intracortical inhibition (SICI) and facilitation (ICF) of the motor cortex in normal subjects. Eight healthy subjects (mean age 26.9 +/- 3.1) underwent 1 Hz frequency rTMS delivered on the right cerebellar hemisphere. Before and after cerebellar rTMS, SICI and ICF were assessed in the motor cortex contralateral to the st…

AdultMaleCerebellumTime Factorsintracortical inhibitioncerebellum1 Hz rTMSmedicine.medical_treatmentDifferential ThresholdStimulus (physiology)motor cortexCerebellar hemisphereMotor systemNeural PathwaysmedicineReaction TimeHumansEvoked potentialAnalysis of VarianceElectromyographyGeneral NeuroscienceNeural InhibitionEvoked Potentials MotorTranscranial Magnetic StimulationElectric StimulationTranscranial magnetic stimulationmedicine.anatomical_structurenervous systemCerebellar cortexFemalePsychologyNeuroscienceintracortical facilitationMotor cortex
researchProduct